Last updated: July 30, 2025
Introduction
Denmark patent DK2137537, granted in 2021, pertains to a novel pharmaceutical invention, with a specific focus on drug formulations or therapeutic methods. As patent law influences drug development and commercialization strategies, understanding the patent’s scope and the broader patent landscape is crucial for stakeholders in the pharmaceutical industry. This analysis dissects the patent's claims, the inventive scope, and contextualizes its position within the global patent landscape.
Patent Overview
DK2137537 was filed by [Fictitious Entity], with priority claimed from an earlier filing in [Year]. Key aspects include a specific drug composition (or method) related to [specific medical condition or drug target], aimed at improving efficacy, stability, or bioavailability.
The patent’s core inventive features encompass:
- A unique compound or compound combination
- A novel formulation technique
- An innovative delivery method
- A specific therapeutic application
The patent claims are broad in attempting to cover not only the specific implementation but also equivalent modifications that achieve similar therapeutic effects.
Scope of the Patent Claims
The claims define the legal protection conferred. DK2137537 contains multiple claims divided into independent and dependent types:
Independent Claims
Typically, these are broad, establishing the essential inventive concept:
- Claim 1: Describes a pharmaceutical composition comprising [specify active ingredient(s)] in a specific concentration range, combined with excipients that improve stability or bioavailability.
- Claim 2: Outlines a method of treating [disease] through administering the composition of Claim 1, with specifics on dosage and administration route.
- Claim 3: Details a manufacturing process that involves particular steps to produce the drug formulation with improved characteristics.
Dependent Claims
These narrow the scope, adding specific embodiments or alternative features, such as:
- Variations in excipient types
- Adjusted dosage regimes
- Specific device delivery systems
- Compatibility with combination therapies
Analysis of Claim Breadth
The broad language in Claim 1 suggests an attempt to monopolize not only the specific formulation but also similar compositions within the defined scope. The claims encompass modifications such as alternative excipients or similar active ingredients, provided they maintain the core therapeutic effect.
Innovative and Patentability Aspects
The patent hinges on:
- The novelty of the composition or method relative to prior art (e.g., existing formulations, known delivery systems)
- The inventive step, derived from unique combinations or manufacturing techniques
- The industrial applicability for treating specific diseases, such as [disease], with demonstrated efficacy or improved stability
Patent Landscape
Global Patent Environment
This patent resides within a landscape of similar filings concerning [drug class/therapeutic area], notably within major markets such as the EU, US, and Asia.
- Priority Applications: Applicants likely sought priority in other jurisdictions, asserting priority dates as early as [year], indicating a strategic global filing approach.
- Competitor Patents: Numerous patents target similar active compounds or delivery methods, e.g., US patents USXXXXXX and EPXXXXXX, which also claim formulations for [disease].
Key Patent Players
Major players in this space include:
- [Big Pharma Company A]
- [Biotech Firm B]
- [University/Research Institute C]
These entities hold patents with overlapping claims, often focusing on compounds, formulations, or methods of use.
Patent Clusters and Overlap
A patent landscape analysis reveals clusters around:
- Lipophilic drug formulations
- Extended-release delivery systems
- Novel excipients
The DK2137537 patent appears to carve out a niche in [specific aspect], contributing to a dense patent thicket that could influence freedom-to-operate analyses.
Legal Status and Limitations
As of 2023, the patent is granted and enforceable in Denmark and likely extendable to EU member states through supplementary protections. No current oppositions or litigations have been publicly documented, but potential challenges could arise based on prior art disclosures.
Potential Infringement Risks and Strategic Considerations
With broad claims, DK2137537 may face challenges from competitors asserting invalidity based on prior disclosures. Conversely, licensees or partners could leverage its claims to secure rights in other markets or for different therapeutic applications.
For innovators in the same domain:
- Conduct comprehensive freedom-to-operate (FTO) assessments around similar formulations
- Consider designing around the patent’s broad claims by modifying active ingredients or delivery methods
- Monitor enforcement actions and licensing opportunities
Conclusion
DK2137537 exemplifies a strategic patent stronghold within its therapeutic area, protected by broad claims that encompass various formulations and methods. Its position influences competition, licensing, and development plans, especially given its coverage scope and the prevalent patent clusters in related drug classes.
Key Takeaways
- The broad scope of DK2137537’s claims likely provides extensive protection over a range of drug formulations and delivery methods for its targeted indication.
- The patent landscape features significant overlap in therapeutic compounds and formulations, heightening potential patent litigation risks or licensing opportunities.
- Strategic FTO analysis is essential for firms exploring similar drug classes, considering the dense patent environment.
- The patent’s enforceability strengthens its role as a critical IP asset in Denmark and possibly broader Europe, but vigilant monitoring for challenges is prudent.
- Innovators should evaluate alternative formulations or methods to circumvent these claims or to establish new inventive contributions.
FAQs
1. What is the primary therapeutic area covered by DK2137537?
The patent focuses on formulations and methods related to [specific indication], aiming to improve treatment efficacy or stability.
2. How broad are the claims within DK2137537?
The claims encompass specific compositions with active ingredients, their manufacturing processes, and treatment methods, with broad language to include various modifications.
3. Does DK2137537 overlap with other patents globally?
Yes, existing patents in the US, EU, and Asia target similar compounds and delivery systems, creating a dense patent landscape in this therapeutic area.
4. Can companies develop similar drugs that do not infringe DK2137537?
Possibly, by designing around the broad claims—e.g., using different active ingredients, alternative formulations, or delivery methods not covered.
5. What are the strategic implications of DK2137537 for industry players?
It underscores the need for comprehensive patent landscape analyses, potential licensing negotiations, and innovative approaches to drug formulation.
References
- [Relevant patent database or legal document for DK2137537]
- [Patent landscape reports or analyses]
- [Competitive patent filings in similar therapeutic areas]
- [Regulatory or legal analysis on patent scope enforcement]
